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BiCyCLE NMES—neuromuscular electrical
stimulation in the perioperative treatment
of sarcopenia and myosteatosis in
advanced rectal cancer patients: design
and methodology of a phase II randomised
controlled trial
Edward T. Pring1,2,3,4* , Laura E. Gould2,5, George Malietzis2,3, Philip Lung2, Mina Bharal2, Tutu Fadodun2,
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Abstract
Background: Colorectal cancer is associated with secondary sarcopenia (muscle loss) and myosteatosis (fatty
infiltration of muscle) and patients who exhibit these host characteristics have poorer outcomes following surgery.
Furthermore, patients, who undergo curative advanced rectal cancer surgery such as pelvic exenteration, are at risk
of skeletal muscle loss due to immobility, malnutrition and a post-surgical catabolic state. Neuromuscular electrical
stimulation (NMES) may be a feasible adjunctive treatment to help ameliorate these adverse side-effects. Hence, the
purpose of this study is to investigate NMES as an adjunctive pre- and post-operative treatment for rectal cancer
patients in the radical pelvic surgery setting and to provide early indicative evidence of efficacy in relation to key
health outcomes.
Method: In a phase II, double-blind, randomised controlled study, 58 patients will be recruited and randomised (1:
1) to either a treatment (NMES plus standard care) or placebo (sham-NMES plus standard care) group. The
intervention will begin 2 weeks pre-operatively and continue for 8 weeks after exenterative surgery. The primary
outcome will be change in mean skeletal muscle attenuation, a surrogate marker of myosteatosis. Sarcopenia,
quality of life, inflammatory status and cancer specific outcomes will also be assessed.
Discussion: This phase II randomised controlled trial will provide important preliminary evidence of the potential
for this adjunctive treatment. It will provide guidance on subsequent development of phase 3 studies on the
clinical benefit of NMES for rectal cancer patients in the radical pelvic surgery setting.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
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Background
Radical multi-visceral resection of pelvic tumours,
known as pelvic exenteration, is being utilised to suc-
cessfully treat a number of intra-abdominal malignancies
[1]. Pelvic exenteration for locally recurrent (LRRC) or
primary advanced rectal cancer has a high morbidity and
mortality. The PelvEx Collaborative analysed data from
1184 patients, who underwent surgery for LRRC, and
found that 2% of patients died within 30 days of surgery
and 32% of patients experienced a major complication
[2]. Despite this high morbidity and mortality, these
complex procedures are increasingly practised in special-
ist centres. Following surgery, these patients enter a
catabolic crisis where incapacitation and high protein
and fat metabolism lead to a marked loss in skeletal
muscle [3–5]. Low skeletal muscle mass (sarcopenia)
and fatty infiltration (myosteatosis) are independently as-
sociated with poorer post-operative outcomes following
surgery for colorectal cancer [6, 7]. The aetiology behind
sarcopenia and myosteatosis is complex and multifactor-
ial and includes inflammatory changes, hormonal
changes, loss of function, fatigue and energy balance [8].
However, strategies to preserve skeletal muscle mass,
quality and function may improve these outcomes.
A meta-analysis of resistance exercise training in pa-
tients with non-metastatic cancer showed significantly
increased skeletal muscle mass [9]. Exercise can also im-
part an anti-inflammatory effect by attenuating the cellu-
lar response to inflammatory stimuli and pro-
inflammatory cytokines such as IL-6, TNFα and TGFβ
[10, 11]. However, exercise programmes following a rec-
tal cancer diagnosis and exenterative surgery are not al-
ways possible or practical due to patient anxieties and
the need to expedite treatment, and the pain or disability
associated with the extensiveness of the surgery itself.
Furthermore, restriction upon rehabilitative resources,
especially physiotherapy, often leaves patients immobile
for long periods with resultant muscle atrophy. An alter-
native approach to traditional physiotherapy could be
functional electrical stimulation (FES) via neuromuscular
electrical stimulation (NMES). This is currently used in
clinical practice for a number of diseases, indeed, at the
National Clinical FES Centre at Salisbury, UK, over 2500
patients are currently undergoing FES [12]. NMES of the
lower-limb muscles requires less motivation than trad-
itional exercise and can be undertaken whilst the patient
is seated or lying down [13]. NMES can be used to
produce a muscle contraction equivalent to 20 to 40% of
a maximum voluntary contraction [14] thus meeting the
criteria of the American College of Sports medicine def-
inition of planned exercise [15].
A study of anterior cruciate ligament [of the knee]
(ACL) reconstruction patients by Hasegawa and col-
league demonstrated NMES, implemented during the
early rehabilitation stage, was effective in maintaining
and increasing muscle thickness and strength in the op-
erated limb [16]. There is also evidence from meta-
analyses that NMES increases muscle strength and
shows potential benefit for joint range of motion, muscle
atrophy, outcomes of ventilation and activity limitations
in critically ill patients [17]. A Cochrane review of
NMES in a number of diseases that cause cachexia
(muscle and fat loss secondary to disease) such as COPD
(Chronic obstructive pulmonary disease), CCF (Congest-
ive cardiac failure), HIV/AIDS and cancer, suggested
that NMES may be an effective treatment for muscle
weakness in adults with advanced progressive disease,
and could be considered as a treatment within rehabili-
tation programmes [18]. Two studies, a phase 2 rando-
mised trial and its pilot study, investigated NMES in
cancer cachexia. Both studies were conducted in patients
with non-small cell lung cancer receiving palliative
chemotherapy [13, 19]. The pilot study [19] demon-
strated positive results however, in the phase 2 study of
49 patients, in which 30 were randomised to NMES,
there were no significant differences in quadriceps
muscle strength, thigh lean mass or physical activity
level between groups [13]. The study team did however
recommend further NMES studies in patients with can-
cer in other settings. Notably these two studies by Mad-
docks’ and colleagues focussed on palliative lung cancer
patients; a surgical complex rectal cancer cohort is fun-
damentally different both by virtue of the impact of the
insult of surgery on muscle but also the radical or cura-
tive nature of the treatment. The differences between
these studies by Maddocks et al. and our study are sum-
marised in Table 1.
Previous studies have examined NMES is the palliative
setting, with inconclusive conclusions regarding efficacy
[13, 19]. No work has yet been done on clinical out-
comes of NMES use in colorectal cancer nor any trial in
the post-operative setting for cancer surgery. A phase II
trial is required to determine whether there is evidence
of a potential benefit prior to justifying a phase III study.
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The previous studies performed in cancer patients have
not examined the relationship to the systemic inflamma-
tory response, nor has there been an assessment of im-
mediate post-operative outcomes. Our study aims to
provide evidence of early indicative evidence of efficacy
in relation to key health outcomes, including skeletal
muscle mass and quality (myosteatosis), markers of sys-
temic inflammation and post-operative recovery out-
comes in rectal cancer patients undergoing radical pelvic
surgery.
Study design, methods and analysis
The study is being undertaken at St Mark’s Hospital, the
sponsor in London North West University Healthcare
(LNWH) NHS Trust. Details of the study sponsor and
their roles and responsibility including auditing, indem-
nity and monitoring can be found in the full trial proto-
col provided as supplementary material, (page VIII and
pages 24-26). Detailed information relating to the trial
authors, management teams and committees including
their roles and responsibilities can be found in the sup-
plementary material full trial protocol under the relevant
headings. Any amendments will be processed and com-
municated through the NHS Health Regulation Author-
ity, Queens Square Research and Ethics committee and
LNWH Research and Development Department, see Full
Protocol pages 24–25 for further details.
Patients will be blinded as to which trial arm they
enter and a sham protocol will be used by the control
arm. Body composition analysis of the images will be
done by automated software used by an assessor blinded
to the intervention to remove operator or interpretation
bias.
Our aim is to compare the effect on muscle of thera-
peutic NMES and current best practice against placebo
NMES and current best practice alone in patients under-




The difference in mean muscle attenuation (MA), of all
skeletal muscle groups captured on the axial CT image
at the level of the third lumbar vertebrate (L3), measured
in Hounsfield units and hence the degree of myosteato-
sis between the pre-operative and 6-month post-
operative CT scan in the NMES treatment group and
the placebo NMES group.
Secondary outcomes
Our main secondary outcomes include change in total
skeletal muscle cross-sectional area, at the L3 level be-
tween treatment and non-treatment groups as well as
between time points for individual patients. Difference
in quality of life between groups using the validated
questionnaires ED-5Q-5L & EORTC QLQ – CR29.
Post-operative complications and length of hospital stay
between both arms and comparison of the systemic in-
flammatory response between each group. A compre-
hensive list of secondary outcomes is shown in Table 2.
Sample size estimation
We powered this phase II trial based upon the primary
outcome. Using data from the Alberta Cancer Registry,
Martin and colleagues described a standard deviation of
MA at 8.6 Hounsfield units (HU) for males and 10.2 HU
for females [20]. We therefore assumed an overall mean
SD of 9.4 HU for both male and female patients. A dif-
ference in MA between groups of 8HU was considered
to be of clinical importance, and the calculation was
based on showing a difference of this size between
groups.
The proposed analysis will adjust the differences at 6
months for the MA values at baseline. To allow for this
approach, this adjusted is included in the sample size
calculation. The size of the association between baseline
and outcome MA values is relatively unknown. A fairly
weak correlation of about 0.3 between the time points
was assumed.
The calculations were performed using a 5% signifi-
cance level and 90% power. Based on the information
above, it was calculated that to show a difference in MA
of 8 units between groups would require a sample size
of 27 per group (54 patients in total).
To allow for an estimated dropout rate of 5%, 58 pa-
tients will be recruited into the study. The dropout rate
of 5% is an estimate based on the fact that the treatment
period is short and supervised for the most part in hos-
pital. For the primary outcome to be measured, we re-
quire the pre- and post-operative CT scans and
therefore anticipate a very low dropout rate due to the
fact these are routine scans and the time period is
Table 1 Differences between BiCyCLE NMES and earlier studies by Maddocks et al.
BiCyCLE NMES study population Maddock’s study population
Post-operative “tumour free” Active cancer
Confined to bed rest Active and mobile population
Intensive inpatient support Outpatient community care
Aiming for recovery up to or beyond baseline Palliative and functionally declining population
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relatively short. The dropout rate for the secondary out-
comes may be higher as the time from surgery pro-
gresses; however, the trial is powered to the primary
outcome and as such, we are not taking into account the
potential drop out from the trial outside this time period
encompassing the primary outcome metrics.
Table 2 Secondary outcomes







The difference in lumbar skeletal muscle
index (LSMI=height / area of skeletal
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third lumbar vertebral axial level
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derived from the third lumbar vertebral
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Pre-surgery
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Any post-operative complication Clavien-Dindo Classification Clavien-Dindo Score
1–5




Inpatient stay post-surgery Days Median length of stay From surgery to hospital discharge
Disease-free
survival
Days to reported first recurrence / death
/ 5 years post-surgery
Days Kaplan-Meier survival
analysis
From date of surgery to 5 years
post-surgery
Overall survival Days to death / 5 years post-surgery Days Kaplan-Meier survival
analysis





Mobility, self-care, usual activities,
Visual analogue scale score










EORTC QLQ - CR29
Function and Symptoms
4 multi-item scales and 19
single items assessing com-
mon symptoms and prob-
lems in colorectal cancer
Change in score
between events
Pre-surgery, 6 and 12 months post-
surgery
Function Berg Balance Scale (BBS) Berg balance score (0–56) Change in BBS score Pre-surgery and 6 months post-
surgery
30 s sit to stand Number of full sit-to stand
actions completed in 30 s
Change in number of
successful actions





Thigh circumference, 5cm above the
superior pole of the patella





Pre- and post-operative mean muscle at-
tenuation (L3) (MMA) and hours of de-
vice usage
Change in MMA/time Linear regression 3–6 months post-surgery
Patient
satisfaction
Free text responses and satisfaction













Phase angle = (Xc/R)*180°/π Cellular resistance (R) and
cellular reactance (Xc)
Change in phase
angle at each time
point
Baseline, day 2 post operatively,
day 28 postoperatively (if in
hospital), day of discharge, first
post-operative follow-up
appointment
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Trial protocol
Recruitment and eligibility screening
The inclusion and exclusion criteria are shown in Table
3. Following diagnosis of locally advanced rectal cancer
patients is discussed in a multidisciplinary team (MDT)
meeting. Some of these patients may be felt to be suit-
able for radical surgery—i.e., surgery performed with the
intention of a cure. If patients are deemed fit for and
consent to surgery then this is performed by one of
three specialist surgeons in St Mark’s Hospital, London,
UK.
Patients who meet the inclusion criteria will be identi-
fied by the clinical team in the colorectal outpatient
clinic or MDT and will then be approached by the study
team with written information on the trial and given the
option to enrol in the study. Consent to take part in the
trial will be obtained at the next outpatient clinic ap-
pointment, which will occur in the weeks preceding sur-
gery. Patients may be included in concomitant studies;
provided agreement is obtained from each trial team.
Further details regarding recruitment the strategy can be
found on pages 21–22 of the Full Protocol (Supplemen-
tary Material).
Detailed information on participant withdrawal and
discontinuation is provided on page 22 of the full proto-
col and within the consent and participant information
sheet (supplementary material).
Randomisation
Randomisation, performed after the assessment of base-
line outcomes, will take place by computer-generated
randomisation software (https://www.sealedenvelope.
com) on a one-to-one basis. Recruitment will be per-
formed by the study team; randomisation will be per-
formed by the study principal investigator. Patients who
are randomised to the either arm will be blinded as to
intervention and will be taught by the research team to
use the stimulator; this will be at their clinic appoint-
ment following consent.
The NMES intervention lasts a total of 10 weeks with
follow-up over 5 years. The trial algorithm is shown in
Fig. 1 and schedule of enrolment, interventions and as-
sessments in Fig. 2.
Blinding
Patients and the assessor of the primary outcome will be
blinded. Patients will be blinded as to which arm they
are in; the devices appear identical with the exception of
a small, coloured plastic tab indicating whether they are
treatment or placebo devices. The assessor of the pri-
mary outcome, a consultant radiologist, will be blinded
as to which trial arm the participant is in; assessment of
the primary outcome is also automated and therefore
will not allow bias. The clinical team caring for the par-
ticipant will not be aware of which trial arm the patient
is in. It is not possible for the individuals providing the
NMES therapy to be blinded as they will need to be
aware of which arm the patient is in in order to provide
effective advice.
Data collection
Surveillance CT scans performed as part of sequential
screening (i.e. not emergency or non-routine imaging)
are performed as standard in this patient group and will
undergo analysis measuring mean muscle attenuation
(myosteatosis) and muscle area (sarcopenia) at the level
of the third lumbar vertebrate. Routine bloods including
CEA (carcinoembryonic antigen) and inflammatory
markers will be measured at each elective routine clinic
visit and these data recorded, these samples will be col-
lected, analysed and disposed of in accordance with the
LNWH NHS Trust policy. Quality of life will be assessed
at 6 and 12 months using validated quality of life ques-
tionnaires (ED-5Q-5L & EORTC QLQ – CR29). The
Berg Balance scale, 30-s sit-to-stand test and 6-min walk
test [21–24] will be used to assess functional outcome
these tests will be performed at the patients 3 months
post operatively clinic appointment. Pre- and post-
operatively, we will measure bilateral thigh circumfer-
ence at 15cm above the superior pole of the patella
(which has been shown in earlier studies to correlate
with muscle volume on MRI) [25]. Bio-impedance ana-
lysis (BIA) will be undertaken at baseline, day 2 post-
operatively, day 28 post-operatively (if in hospital), day
of discharge and first post-operative follow-up appoint-
ment. We will record data from the device satisfaction
questionnaires from both groups. Standard outcome
data and covariates to be collected are shown in Table 4.
Table 3 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
○ Adults age 18 and above
○ Male or female
○ Primary or recurrent locally advanced rectal cancer amenable
to elective radical exenterative surgery
○ ASA grades I–III
○ Able and willing to consent
○ in other concurrent trials is acceptable—following discussion
with trial team of both studies
○ Lack of patient consent
○ Widespread metastases not amenable to curative resection
○ Contraindication to NMES
○ Pre-existing neuromuscular degenerative disease
○ Participation in other trials where agreement on participation not made in
advance by trial teams
○ Patients with solitary colon cancer above the level of the peritoneal reflexion
which does not require complex pelvic surgery
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Data collection will be undertaken using a case re-
port form (CRF) designed by the investigators; the
data will be transferred from the CRF to a Microsoft
Excel Database (Microsoft Corporation, Redmond,
Washington, USA), stored in the LNWH NHS Trust
secure network. All collected data will be reviewed by
the principal investigator prior to analysis and specific
searches on written notes or electronic record systems
will be made to address any missing data points. The
data collected as part of this trial will be subject to
review by the independent Trial Data Monitoring
committee on request as per the Data Monitoring
Charter (supplementary material).”
Information on data management, storage and cur-
ation is available in the Full Trial Protocol (supplemen-
tary material, page 17).
Data monitoring and compliance
A sponsor-approved independent data monitoring com-
mittee (IDMC) has been appointed to the trial as part of
good trial governance to ensure safety, scientific validity
and integrity of the trial. The data monitoring commit-
tee will have access to raw data and will review any sig-
nificant adverse events or safety concerns within the
trial. The IMDC will make recommendations and report
directly to the sponsor representative and chief
Fig. 1 Study algorithm
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investigator. The trial Data Monitoring Charter is in-
cluded for review within the supplementary material.
Further information on data management and security
and storage are available in the Full Protocol, supple-
mentary material pages 17, 26 and appendix 4.
Study intervention
Stimulation of muscle
We will endeavour to stimulate two major muscle
groups during the study, the quadricep muscles and
paraspinal muscles. The muscles of the quadriceps, par-
ticularly vastus lateralis and vastus medialis, will be
stimulated in both legs; this will be performed with a
view to preserving muscle mass and encouraging earlier
ambulation and better function.
We will also stimulate the erector spinae muscles and
the muscles of the lower back. The reason for this is
twofold: firstly, it is felt that some of the earliest muscles
to atrophy following surgery or during bed rest are the
core muscles of the back especially as these patients will
not be sitting up or utilising these important supportive
muscles in the first stages of their recovery. Patients are
nursed on their side during the first 14 days following
major pelvic surgery, which means they tend not to use
Fig. 2 Schedule of enrolment, interventions and assessments
Table 4 Outcomes and covariates
Demographics
o Patient age
o Patent birth year
o Patient gender
o Patient ethnicity coding
o Weight
o Height
o Body mass index
Outcome measures
o 90-day post-operative complications (Clavien-Dindo classification
(18))
o Disease outcomes including 30-day survival
o Death / recurrence / disease-free survival
o Patient compliance diary data
o Device usage
Disease
o ASA grade (American College of Anaesthesiology) physical status
o Past medical history (other or previous illnesses and surgery)
Body composition parameters




o Type of cancer (primary/recurrent cancer, location and subtype on
histology)
o Grade of cancer
o Stage of cancer
Inflammatory markers
o Serum C-reactive protein




o Details of surgery
o Chemotherapy
o Radiotherapy
Patient-specific and functional outcomes
o Quality of life
- ED-5Q-5L
- EORTC QLQ – CR29
o Patient satisfaction
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their core muscles to flex or extend their back or sup-
port their weight leading to loss. This lateral position
however would afford easy access to place the electrodes.
Secondly, we are focussing on the muscle groups at the
third lumbar vertebrate—the level this stimulation would
take place, using the device in this location, would give
us the best chance of demonstrating the benefits of the
device with regard to muscle preservation. This site is
well away from the operative site and tumour bed in
these individuals and therefore there would be no risk of
stimulating the tumour bed whilst using the device in
this position.
Neuro-muscular stimulation will be delivered by a
MicroStim Exercise Stimulator MS2v2 (Odstock Medical
Limited (OML), Wiltshire, UK) using two self-adhesive
electrodes placed on the anterior thigh over the body of
the vastus medialis and lateralis and the muscles of the
lower back. At their second clinic appointment at St
Mark’s, patients will be trained by the research fellow or
other competent research team member (physiotherapist
or specialist nurse) to use the NMES. A study-specific
instruction leaflet will be given to this group along with
the standard instruction manual by OML.
The programme will commence pre-operatively and
consist of daily stimulation to one thigh at a time
followed by the lower back each for 15 min, increasing
to 60 min within 1 week as tolerated. One treatment ses-
sion for both thighs would last between 60 and 90 min
in total per day—this can be taken in up to three
discrete sessions. Treatment will last for 2 weeks pre-
operatively and 8 weeks postoperatively.
NMES would be used preoperatively to familiarise pa-
tients with and increase confidence in using the device
prior to surgery and to aid prehabilitation.
Intervention training
Training in using the MicroStim 2v2 has been under-
taken by the trial principal investigator at the device
manufacturer, OML. Patient training will be conducted
by the study PI or a trained member of their study team.
Patients using the device will be observed and educated
on correct usage by the study team. They will be asked
to keep a usage diary and the device will record usage
statistics via an inbuilt recorder. These data will feed
into the analysis to provide a dose response model
within the final analysis.
The therapeutic NMES arm
Patients will be blinded as to which arm of the trial they
are in. Therapeutic NMES will be delivered by a Micro-
Stim Exercise Stimulator MS2v2 using two self-adhesive
electrodes placed on the anterior thigh over the body of
the vastus medialis and vastus lateralis muscles and the
lower back.
Pulse waveform (symmetrical biphasic squared), fre-
quency (40 Hz), and width (350 microseconds) would be
used for the duration of treatment with the NMES. The
amplitude (device output 0–120 mA, tested across
1000Ω) will be set to elicit a visible and comfortable
muscle contraction; patients will be encouraged to sub-
sequently increase the amplitude as tolerated. A “com-
pliance diary” will be kept by the patients during their
treatment period detailing their time spent using the de-
vice and the settings at which they are using it.
This programme is adapted from one found to be of
benefit in a pilot study of patients with non-small cell
lung cancer which itself was based on an NMES exercise
programme developed for patients with COPD. The
stimulation parameters were selected to favour gains in
function and strength over endurance (frequency), min-
imise skin irritation (pulse width) and allow for sufficient
recovery of the muscles between contractions (duty
cycle) [13, 19].
The placebo NMES arm
A modified model of MicroStim Stimulator MS2v2
(Odstock Medical Limited, Wiltshire, UK) will be pro-
vided to the placebo group who will apply two self-
adhesive electrodes placed on the anterior thigh over the
body of the vastus medialis and vastus lateralis muscles
and the lower back as in the treatment group. This pla-
cebo device will be programmed to provide sub-
therapeutic electrical stimulation. The device manufac-
turers have tailored a programme to come on and off at
specified timings with ramps of specified duration. The
placebo devices output is restricted to around 18V and
this gives little or no muscle recruitment. Patients will
however perceive a sensation of electrical stimulation.
Both groups
Patients in both arms will receive standard care includ-
ing enhanced nutritional support (parenteral nutrition
for a minimum of 5 days or until taking sufficient calo-
ries enterally) and physiotherapy in line with current
guidelines and local hospital practices. Routine daily
blood tests for inflammatory markers will be taken until
discharge.
Assessment of outcomes
Patients from both the treatment and control arms will
receive standard 5-year follow-up. Histopathological data
will be recorded following processing of the resected
specimens by the pathologist. Quality of life data, patient
satisfaction, bio-impedance analysis, CT Body compos-
ition and functional measurements will be taken as de-
tailed below.
As a phase II trial, we aim to determine the short-term
effects on our primary outcome; as such, our primary
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analysis to identify changes within the pre- and post-
operative CT scans and analysis of NMES satisfaction
and the initial inflammatory data, functional and quality
of life data will take place at 6 months following the re-
cruitment of the final patient with subsequent reporting
and publication of these results. We will then continue
long-term follow-up for the standard clinical 5-year
follow-up period or until patient death. Final analysis ex-
ploring the effect of intervention on 5-year overall and
disease-free survival will take place at 5 years following
recruitment of the final patient.
Body composition assessment
CT body composition parameters
CT image analysis using SliceOmatic version 5.0 soft-
ware (TomoVision, Montreal, Quebec, Canada) will be
performed. Total skeletal muscle and visceral adipose
tissue surface area (cm2) will be evaluated on a single
image at the third lumbar vertebra (L3) using HU
thresholds of −29 to 150 for skeletal muscle, −50 to 150
for visceral adipose tissue (VAT) and −190 to −30 for
subcutaneous adipose tissues. CT body composition ana-
lysis of all the included images will undergo automated
segmentation using the ABACS L3 automated plug-in
software [26] (Voronoi Health Analytics, BC, Canada),
which complements SliceOmatic. The automated
process will be directed by a radiologist who will be
blinded to the treatment group of individual patients.
The automated segmentation process provided by the
ABACS L3 plug-in also removes the possibility of oper-
ator bias in the analysis of the images. The sum of skel-
etal cross-sectional muscle areas will be normalised for
stature (m2) and reported as lumbar skeletal muscle
index (LSMI) (cm2/m2). Outcome variables will be con-
tinuous; categorical variables will be defined from these
data using the cut-off values described earlier [20, 27,
28].
Anthropometrics and bio-impedance analysis
Bio-impedance analysis (BIA) will be undertaken using a
SECA mBCA 525 analyser (SECA, Hamburg Germany).
This will be performed at baseline, day 2 post-surgery,
either hospital discharge or at 28 days post-surgery
(whichever is first) and at 6 months. Patients will
undergo analysis in a fasted state. Posterior upper arm
skin fold thickness and waist circumference will be per-
formed at baseline and 6 months. We will measure thigh
circumference at 15cm above the superior pole of the
patella (which has been shown in earlier studies to cor-
relate with muscle volume on MRI) [25]. Phase angle
from BIA and patient BMI will be utilised as categorical
variables with other outcome variables being continuous.
Functional assessment
It is important that we measure not only the anatomical
effects of NMES, i.e. increased muscle mass on CT and
anthropometric changes, but we identify whether these
patients demonstrate both a functional and physiological
improvement. To that end, we will assess functionality
preoperatively at diagnosis and post-operatively at 3
months using the validated instruments of the 6-min
walk test [24], 30 s sit-to-stand test [23] and Berg Bal-
ance scale (BBS) [21, 22]. These assessments will be
undertaken in the complex cancer clinic by either a spe-
cialist physiotherapist or research fellow. These data will
be treated as continuous outcome variables with the ex-
ception of BBS which will be categorical.
Quality of life
We will examine quality of life and patient experience of
using the device. Quality of life will be measured using
the validated questionnaires described above. On com-
pleting the intervention, participants will complete a
questionnaire on compliance, comfort and usability of
the device in the postoperative setting. Qualitative data
and free text comments from this will also be collected.
Systemic inflammatory response
To monitor the inflammatory response, we will use
commonly utilised postoperative inflammatory markers,
namely c-reactive protein(CRP) and values derived from
the full blood count and biochemistry including
neutrophil-to-lymphocyte ratio (NLR) and modified
Glasgow Prognostic Score (mGPS). These inflammatory
markers are well-established metrics linked to both sar-
copenia, myosteatosis and prognosis in colorectal cancer
[29–31]. We have chosen these markers for a number of
reasons; they are routinely taken and cost-effective and
allow for comparison with substantial historical data.
We may also require results from other trusts, due to
the national spread of our patient population, and we
cannot support them in obtaining non-routine tests as
part of this study.
Planned statistical analyses
This study will be performed in line with the CONSORT
criteria (http://www.consort-statement.org/consort-201
0). Initially outliers, patterns of attrition and missing
data will be identified using a combination of graphical
displays and descriptive statistics allowing decisions on
the assumption of normality. The primary analysis will
be of observed data only, with patients with missing data
omitted from the analysis. If the primary outcome has
>10% missing data points, a sensitivity analysis will be
performed using multiple imputation to estimate the
missing values.
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Data will be analysed by a statistician blinded to the
intervention. Analyses of primary and secondary end-
points will be based on the full analysis set defined ac-
cording to the intention to treat principle. Safety analysis
will be performed for the on all enrolled individuals with
disclosure of any significant adverse events. The full ana-
lysis set consists of all participants consented and rando-
mised with valid baseline assessments. Participants will
be analysed according to the study arm they were
assigned at randomisation.
The primary outcome is myosteatosis at 3–6 months
post-surgery, derived from the mean muscle attenuation
on CT body composition analysis. This will be analysed
using analysis of covariance (ANCOVA), with muscle at-
tenuation values at baseline used as a covariate in the
analysis.
The secondary outcome measures measured on a con-
tinuous scale, and with a baseline measurement will be
analysed using equivalent methods as the primary out-
come. For continuous outcomes with no baseline meas-
urement, group comparisons will be made using either
the unpaired t-test or Mann-Whitney test, depending on
data distribution. The chi-square test, or Fisher’s exact
test, will be used to compare categorical outcomes be-
tween the study groups.
Significance will be assumed when p<0.05.
Adverse event reporting
Adverse event reporting in this trial is carried out in ac-
cordance with the NHS Health Regulation Authority
(HRA). All serious adverse events (SAE), whether or not
related to participation in the trial, will be reported im-
mediately to the trial sponsor; these will be reviewed by
the trial sponsor and should further investigation be re-
quired the trial sponsor may pause the trial to carry out
investigation. Should a SAE occur as a direct result of
the trial device or as a direct result of participation in
the trial the trial will be paused and a non-CTIMP safety
report form will be submitted to the relevant research
and ethics committee with 15 days of the Chief Investi-
gator becoming aware of the event. In this instance, the
SAE report will be unblinded as required by the HRA.
Patient-reported adverse events deemed expected or
non-serious will be reported in the final publications
arising from this trial, we expect many of these minor
events to be reported in the patient satisfaction
questionnaire.
Discussion
Patients who undergo major pelvic surgery have limited
mobility due to postoperative pain and disability. These
patients are therefore at much greater risk of suffering
from muscle wasting than patients undergoing more
routine colorectal surgery. This is a result of greater loss
of function, greater immobility and potentially a more
profound immunogenic inflammatory response.
Currently, these patients receive postoperative physio-
therapy; due to limited time, postoperative pain, patient
choice and resource availability, it is unlikely that the pa-
tients are exercised to their full potential. A prescribed
programme with a NMES device would allow patients to
choose when they undertake muscle stimulation exercise
for example once they had received adequate analgesia
or at a time convenient to them. This would hopefully
improve compliance and bring about a hypertrophic re-
sponse in the muscle.
We know that in muscle disuse in healthy individuals
NMES may provide an effective treatment to preserve
muscle volume [16]. Maddocks’ work in cancer patients
[13, 19] however did not demonstrate a significant in-
crease in muscle volume and therefore one may question
the rationale behind use in this patient group (these dif-
ferences are summarised in Table 1). The cancer popula-
tion in these studies is different from our own in a
number of respects beyond the diagnosis alone and as
such we may find NMES to be a more suitable interven-
tion in our patient group. Maddocks’ work was per-
formed in a palliative population with active cancer
whilst postoperatively our patients will be theoretically
cancer free with perhaps a few exceptions in patients
who have solitary metastases (which, by the criteria of
inclusion, are amenable to curative treatment). In view
of their palliative status, Maddocks’ population would be
expected to decline in health over time whilst our popu-
lation would be expected to make a recovery up to or
even beyond their preoperative state and therefore
NMES may increase the rate of or facilitate this recov-
ery. Our population is confined to bed rest for over a
week’s duration following surgery and therefore activity
provided by NMES may help arrest the muscle loss asso-
ciated with disuse as in Hasegawa’s population whose
anterior cruciate ligament repair cohort was subject to
muscle loss through disuse rather than disease [16]. Fi-
nally, our patients will receive intensive inpatient sup-
port by the ward physiotherapists and the research team;
they will receive positive reinforcement of their use of
the device and will be asked to complete an exercise
diary which the physiotherapy team, will review with
them at each point they receive formal physiotherapy
sessions. This level of direct input and positive
reinforcement is notably more than in the previous
NMES studies of Maddocks’ and therefore we would
hope compliance and correct usage would be increased.
The inflammatory effects of exercise are known to be
paradoxical in that exercise drives both a pro and anti-
inflammatory response [32, 33]. We propose that the
metabolic result of exercise in cancer patients will drive
a beneficial anti-inflammatory response. This
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immunomodulation may in part help support the body’s
immune system in the early stages of post-surgical re-
covery and as such may potentially support the cellular
immune system in being able to identify and destroy ma-
lignant cells shed at the time of surgery.
In our patient group, NMES will potentially allow a
higher degree of exercise than the patients would other-
wise be able to undertake due to their incapacity. Our
hope is that this promotes muscle preservation, allowing
earlier mobilisation and a more expedient return to
“normal” exercise and function, further reinforcing the
preservation of muscle mass. Increased muscle mass and
quality are associated with improved long-term outcome
such as disease-free survival [6] we intend to follow our
cohort for 5 years to see if NMES provides evidence to
support improvement in these oncological outcomes
through muscle preservation.
Summary
Exercise in healthy individuals leads to increased muscle
mass; exercise can bring about an anti-inflammatory ef-
fect due to muscle physiology thus obfuscating a key
pathway driving secondary sarcopenia. Preservation of
muscle mass through early post-operative intervention
with NMES would allow a more rapid return to normal
exercise and normal function leading to greater muscle
preservation and subsequently improved outcomes.
Trial status
BiCyCLE NMES is currently recruiting patients; recruit-
ment began on the 31 May 2019 and is expected to be
completed by March 2021. Protocol version 6 dated 05/
06/20 is currently approved by the research ethics com-
mittee and the HRA.
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